FDA posted a draft guidance for comment today "Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection"
This one is pretty straight forward in its intent – to aid drug manufacturers who chose to respond to a Form 483 received at the end of a CGMP inspection. It covers drugs regulated by Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Veterinary Medicine (CVM). The Introduction notes that the "Recommendations regarding the structure and content of a response to an FDA 483 are intended to support clear communication." Along with covering the content of the response, much of the draft guidance addresses how to address the 483 observations, including understanding the observations, management's responsibilities, investigations plans and conducting investigation, CAPAs (developing, implementing, evaluating effectiveness). Overall, this will be of interest and an aid to those in the CGMP space but the content will be applicable to other GxP groups receiving 483s.
Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspectiohttps://www.fda.gov/regulatory-information/search-fda-guidance-documents/responding-fda-form-483-observations-conclusion-drug-cgmp-inspection
#fda #483ResponseGuidance
------------------------------
Mark Arnold Ph.D., FAAPS
Westampton, NJ
[email protected]Bioanalytical Solution Integration
LinkedIn:
https://www.linkedin.com/in/markearnoldphd/Website & Blog: Bioanalysis & Biomarkers <bioanalysisandbiomarkers.blogspot.com>
------------------------------
</bioanalysisandbiomarkers.blogspot.com>